Eleftherios Mylonakis, MD and Panayiotis D. Ziakas, MD, MSc, PhD
Allocating resources for interventions requires consensus among stakeholders with a plurality of perspectives about how to weigh antimicrobial stewardship interventions’ risks and benefits.
AMA J Ethics. 2021;23(8):E631-638. doi:
10.1001/amajethics.2021.631.
Insurers’ decisions about which services to cover are often based on economic models that are seemingly objective but neglect factors affecting people who are economically disadvantaged.
AMA J Ethics. 2021;23(8):E648-652. doi:
10.1001/amajethics.2021.648.
Dr Nat Mulkey and Dr Carl G. Streed Jr join Ethics Talk to discuss their article coauthored with Dr Barbara M. Chubak, "A Call to Update Standard of Care for Children With Differences in Sex Development."
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Priorities far beyond generating morbidity or mortality data are needed to improve patients’ experiences, innovate metrics, and advance surgical palliation as a field.
AMA J Ethics. 2021;23(10):E806-810. doi:
10.1001/amajethics.2021.806.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Neurophysiological sequelae of childhood trauma can express later in the lives of patients experiencing homelessness, especially during informed consent.
AMA J Ethics. 2021;23(11):E847-851. doi:
10.1001/amajethics.2021.847.